Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Middle East respiratory syndrome coronavirus vaccine - Vaccitech

Drug Profile

Middle East respiratory syndrome coronavirus vaccine - Vaccitech

Alternative Names: ChAdOx1 MERS vaccine; MERS vaccine - Vaccitech; MERS-CoV vaccine – Vaccitech; VTP-500

Latest Information Update: 27 Dec 2019

At a glance

  • Originator Korea Investment Partners; Vaccitech
  • Developer University of Oxford; Vaccitech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 23 Dec 2019 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (In volunteers) in Saudi Arabia (IM)
  • 27 Sep 2018 Janssen Vaccines & Prevention B.V., the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford enter into a collaboration to develop and manufacture ChAdOx1 vaccine against Middle East Respiratory Syndrome Coronavirus
  • 27 Sep 2018 Oxford University in-licenses certain rights to Middle East respiratory syndrome coronavirus vaccine from Vaccitech

Development Overview

Introduction

ChAdOx1 MERS vaccine (also known as VTP 500), a vaccine against Middle East respiratory syndrome (MERS) Coronavirus (MERS-CoV), is being developed by Vaccitech (a spin-out company of the University of Oxford) for the treatment of MERS infections. Vaccitech has in-licensed the ChAdOx1 MERS vaccine from the Jenner Institute, University of Oxford. Clinical development is underway in the UK and Saudi Arabia.

Company Agreements

In September 2018, University of Oxford and Vaccitech (spun-out from University of Oxford) entered into a licensing agreement for Middle East respiratory syndrome coronavirus (MERS) vaccine. Under the terms of agreement Vaccitech granted certain rights for this vaccine to Oxford for its development for non-profit public-health use. [1]

In September 2018, Janssen Vaccines & Prevention BV entered into a research and development agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Jenner Institute at the University of Oxford, to develop and manufacture a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections. Under the terms of the agreement, Janssen will provide its expertise and technology for vaccines development to advance vaccines against the Lassa and Nipah viruses. CEPI will provide $US14.6 million to Janssen and the Jenner Institute for the ongoing clinical development of adenovirus-vectored MERS-CoV vaccine, ChAdOx1, through phase I studies and manufacturing of clinical trial supplies. CEPI will have the option to provide additional funding for phase II development and manufacturing of an investigational vaccine stockpile available for use in the event of a MERS outbreak, based on the phase I study results. Janssen's proprietary PER.C6® vaccine manufacturing platform will be used for manufacturing for multiple types of vaccines and the creation of this stockpile. CEPI will provide an additional $US4.1 million to fund early-stage, preclinical development of candidate vaccines for the Lassa and Nipah viruses. [2]

Key Development Milestones

In December 2019, Jenner Institute and the King Abdullah International Medical Research Center (KAIMRC) initiated a phase I trial to assess the immunogenicity and safety of Middle East respiratory syndrome coronavirus vaccine in healthy volunteers in Saudi Arabia [3] [4] .

In March 2018, Vaccitech initiated a phase I trial to assess the immunogenicity and safety of MERS vaccine in healthy volunteers (MERS001; NCT03399578). The open label trial is enrolling 24 participants in United Kingdom [5] .

ChAdOx1 MERS vaccine has showed its capacity of inducing antibodies to a level which are protective in animal models.

Financing information

In December 2018, Vaccitech received £6 million investment from GeneMatrix and Korea Investment Partners and plans to use the investment to advance ongoing clinical projects and expand its research and development [6] .

In September 2018, The Coalition for Epidemic Preparedness Innovations (CEPI) awarded $US14.6 million to Oxford and Janssen to support manufacturing of a phase II batch and prepare for stockpiling of a MERS-CoV vaccine candidate [1] .

In January 2018, Vaccitech secured £20 million ($US27.1 million) in Series A financing, and plans to use the funding to expand its business, and to progress its influenza and prostate cancer programmes through phase II by the end of 2019, and advance three other research programmes into clinical development [7] .

Drug Properties & Chemical Synopsis

  • Route of administration IM
  • Formulation unspecified
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Middle East respiratory syndrome coronavirus - In volunteers Phase I Saudi Arabia IM / unspecified University of Oxford, Vaccitech 23 Dec 2019
Middle East respiratory syndrome coronavirus - Prevention Phase I United Kingdom IM / unspecified University of Oxford, Vaccitech 14 Mar 2018

Commercial Information

Involved Organisations

Organisation Involvement Countries
Vaccitech Originator United-Kingdom
Korea Investment Partners Originator South-Korea
Korea Investment Partners Owner South-Korea
Vaccitech Owner United-Kingdom
University of Oxford Licensee England
GeneMatrix Funder South-Korea
Coalition for Epidemic Preparedness Innovations Funder Norway
Janssen Vaccines and Prevention B.V Collaborator Netherlands
Janssen Vaccines Collaborator South-Korea

Future Events

Expected Date Event Type Description Updated
31 Jan 2018 Trial Update University of Oxford plans a phase I trial for Middle East respiratory syndrome coronavirus (Prevention) in United Kingdom in January 2018 (NCT03399578) (700292434) 10 Aug 2018

Development History

Event Date Update Type Comment
23 Dec 2019 Phase Change - I Phase-I clinical trials in Middle East respiratory syndrome coronavirus (In volunteers) in Saudi Arabia (IM) [3] Updated 27 Dec 2019
27 Sep 2018 Licensing Status Janssen Vaccines & Prevention B.V., the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford enter into a collaboration to develop and manufacture ChAdOx1 vaccine against Middle East Respiratory Syndrome Coronavirus [2] Updated 08 Oct 2018
27 Sep 2018 Licensing Status Oxford University in-licenses certain rights to Middle East respiratory syndrome coronavirus vaccine from Vaccitech [1] Updated 05 Oct 2018
14 Mar 2018 Phase Change - I Phase-I clinical trials in Middle East respiratory syndrome coronavirus (Prevention) in United Kingdom (IM) (NCT03399578) Updated 10 Aug 2018
25 Jan 2018 Trial Update University of Oxford plans a phase I trial for Middle East respiratory syndrome coronavirus (Prevention) in United Kingdom in January 2018 (NCT03399578) Updated 10 Aug 2018
15 Jan 2018 Trial Update Vaccitech plans a phase I trial for Middle East respiratory syndrome coronavirus (Prevention) in United Kingdom Updated 18 Jan 2018
10 May 2016 Phase Change - Preclinical Preclinical trials in Middle East respiratory syndrome coronavirus in United Kingdom (Parenteral) Updated 21 Oct 2016

References

  1. Vaccitech licenses MERS rights to Oxford University: CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines.

    Media Release
  2. Johnson & Johnson Announces New Collaboration to Advance Novel Vaccine for MERS.

    Media Release
  3. New MERS vaccine clinical trial starts in Saudi Arabia.

    Media Release
  4. Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

    ctiprofile
  5. A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers

    ctiprofile
  6. Vaccitech receives Lstg6M investment from GeneMatrix and Korea Investment Partners.

    Media Release
  7. Vaccitech secures Lstg20m Series A with GV, OSI and Sequoia China.

    Media Release
Back to top